These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1348584)

  • 1. Treatment of extrapyramidal side effects with terguride.
    Filip V; Marsálek M; Hálková E; Karen P
    Psychiatry Res; 1992 Jan; 41(1):9-16. PubMed ID: 1348584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.
    Olbrich R; Schanz H
    Pharmacopsychiatry; 1988 Nov; 21(6):389-90. PubMed ID: 2907647
    [No Abstract]   [Full Text] [Related]  

  • 4. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.
    Friedman JH
    Mov Disord; 1994 May; 9(3):321-4. PubMed ID: 7913739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The psychological consequences of tardive dyskinesia. The effect of drug-induced parkinsonism and the topography of the dyskinetic movements.
    Brown KW; White T
    Br J Psychiatry; 1991 Sep; 159():399-403. PubMed ID: 1683594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial dopamine agonist therapy of levodopa-induced dyskinesias.
    Baronti F; Mouradian MM; Conant KE; Giuffra M; Brughitta G; Chase TN
    Neurology; 1992 Jun; 42(6):1241-3. PubMed ID: 1351273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.
    Olbrich R; Schanz H
    J Neural Transm Gen Sect; 1991; 84(3):233-6. PubMed ID: 1679338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of manual dominance in patients with neuroleptic-induced movement disorders.
    Kern RS; Green MF; Satz P; Wirshing WC
    Biol Psychiatry; 1991 Sep; 30(5):483-92. PubMed ID: 1681944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Handedness as a risk factor for neuroleptic-induced movement disorders.
    Brown KW; White T; Anderson F; McGilp R
    Biol Psychiatry; 1992 Apr; 31(7):746-8. PubMed ID: 1350923
    [No Abstract]   [Full Text] [Related]  

  • 15. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
    Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
    Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490.
    Boerner RJ; Klement S
    Wien Med Wochenschr; 2004 Nov; 154(21-22):508-10. PubMed ID: 15638068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced parkinsonism: relationship to age at onset of schizophrenia.
    Sandyk R; Kay SR
    Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fine force instability: a quantitative measure of neuroleptic-induced dyskinesia in the hand.
    Caligiuri MP; Lohr JB
    J Neuropsychiatry Clin Neurosci; 1990; 2(4):395-8. PubMed ID: 1983784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.
    Barnes TR; Liddle PF; Curson DA; Patel M
    Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.